Neurocrine demonstrated strong commercial performance with significant revenue growth and successful product launches. The company is expanding its market presence and advancing its pipeline, although pricing pressures and regulatory uncertainties pose challenges.

Company Guidance -

Q3 2025

In the second quarter of 2025, Neurocrine Biosciences reported $682 million in net product sales, marking a 17% year-over-year growth. The company's lead product, INGREZZA, generated $624 million in sales, reflecting a 15% sequential growth and an 8% year-over-year increase. This growth was attributed to strategic investments in market access and a sales force expansion, which resulted in a record number of new patient starts and total prescriptions. The company also highlighted the successful launch of CRENESSITY, which achieved $53 million in sales in Q2, up from $15 million in Q1. Over 1,000 new treatment forms have been submitted since the launch, with more than 75% of dispensed prescriptions being reimbursed. Neurocrine has adjusted its net sales guidance for INGREZZA to $2.5 billion to $2.55 billion for 2025, accounting for anticipated double-digit volume gains, partially offset by higher gross-to-net impacts. The company remains focused on driving revenue growth, advancing its R&D programs, and maintaining a strong balance sheet with $1.8 billion in cash.

Strong Revenue Growth

Neurocrine reported $682 million in net product sales during Q2 2025, representing 17% year-over-year growth.

Impressive Launch of CRENESSITY

CRENESSITY net sales grew from $15 million in Q1 2025 to $53 million in Q2 2025, surpassing internal expectations with over 75% of dispensed prescriptions being reimbursed.

INGREZZA Market Expansion

INGREZZA sales reached $624 million in Q2 2025, with record numbers of new patient starts and total prescriptions, contributing to an 8% year-over-year sales growth.

Robust Pipeline Developments

Multiple Phase III programs launched for osavampator and NBI-'568, with anticipated top line data readouts in the 2027-2028 timeframe.

Successful Medicare Formulary Expansion

Neurocrine expanded Medicare formulary coverage for INGREZZA to approximately 70% of Medicare beneficiary lives in the TD market.

Strong Cash Position

Neurocrine has $1.8 billion in cash and a strong balance sheet to support continued growth strategies.

Neurocrine (NBIX) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

NBIX Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Nov 04, 2025	2025 (Q3)	1.58 / -	1.24	―	―	―
Jul 30, 2025	2025 (Q2)	0.96 / 1.06	0.63	68.25% (+0.43)
May 05, 2025	2025 (Q1)	0.54 / 0.08	0.42	-80.95% (-0.34)
Feb 06, 2025	2024 (Q4)	1.61 / 1.00	1.44	-30.56% (-0.44)
Oct 30, 2024	2024 (Q3)	1.50 / 1.24	0.82	51.22% (+0.42)
Aug 01, 2024	2024 (Q2)	1.13 / 0.63	0.95	-33.68% (-0.32)
May 01, 2024	2024 (Q1)	1.10 / 0.42	-0.79	153.16% (+1.21)
Feb 07, 2024	2023 (Q4)	1.21 / 1.44	0.88	63.64% (+0.56)
Oct 31, 2023	2023 (Q3)	1.04 / 0.82	0.69	18.84% (+0.13)
Aug 01, 2023	2023 (Q2)	0.81 / 0.95	-0.18	627.78% (+1.13)

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

NBIX Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Jul 30, 2025	$136.76	$128.23	-6.24%
May 05, 2025	$109.75	$118.92	+8.36%
Feb 06, 2025	$150.51	$122.62	-18.53%
Oct 30, 2024	$116.19	$124.33	+7.01%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Neurocrine (NBIX) report earnings?

Neurocrine (NBIX) is schdueled to report earning on Nov 04, 2025, After Close (Confirmed).

What is Neurocrine (NBIX) earnings time?

Neurocrine (NBIX) earnings time is at Nov 04, 2025, After Close (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is NBIX EPS forecast?

NBIX EPS forecast for the fiscal quarter 2025 (Q3) is 1.59.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing